Gland Pharma has reported a strong financial performance for the second quarter of FY27, with consolidated revenue rising 23% year-on-year and profit after tax (PAT) jumping 58%, powered by robust growth across its businesses, particularly its contract development and manufacturing organisation (CDMO) segment.

 

The injectable-focused pharmaceutical company posted revenue from operations of Rs 18,336 million for the quarter ended September 30, 2026, compared with Rs 14,869 million in the corresponding quarter last year.

 

Net profit surged to Rs 2,908 million from Rs 1,837 million a year ago, while earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 53% to Rs 4,804 million.

 

Adjusted EBITDA rose 50% to Rs 5,030 million, with the adjusted EBITDA margin expanding to 27% from 23% in the year-ago quarter.

 

The company's profit before tax (PBT) increased 52% to Rs 4,309 million, while gross profit grew 25% to Rs 11,638 million.

 

Commenting on the performance, Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “We delivered another quarter of strong growth, with revenue increasing 23% year-on-year and profit after tax growing 58% year-on-year, driven by strong execution across our businesses. 

 

"Our CDMO business grew 31% year-on-year, supported by expanding customer engagements, strategic partnerships and a robust opportunity pipeline. With continued investments in manufacturing capabilities, innovation and capacity expansion, we remain well positioned to capitalize on growing global outsourcing opportunities and create sustainable long-term value for shareholders.”

 

The CDMO business emerged as a key growth driver, contributing 45% of Gland Pharma's Q2 revenue and registering a 31% year-on-year increase.

 

The critical injectables business, which includes B2B and B2C operations, accounted for the remaining 55% of revenue and grew 18% during the quarter.

 

The company continued to invest in research and development, with quarterly R&D expenditure standing at Rs 1,077 million, reflecting its focus on innovation and strengthening its manufacturing capabilities.

 

For the six months ended September 30, 2026, Gland Pharma reported a 21% increase in revenue to Rs 36,339 million, compared with Rs 29,925 million in the corresponding period last year.

 

EBITDA rose 43% to Rs 9,734 million, while adjusted EBITDA also grew 43% to Rs 10,132 million.

 

Profit before tax increased 45% to Rs 8,659 million, while PAT jumped 52% to Rs 6,077 million against Rs 3,992 million in the first half of FY26.

 

The results underscore sustained growth across the company's business segments, supported by improved operating performance and a strong contribution from its CDMO operations.

 

With continued investments in capacity expansion, manufacturing infrastructure and innovation, Gland Pharma is looking to strengthen its position in the global pharmaceutical outsourcing market.